Late-onset pompe disease in Iran: A clinical and genetic report

Muscle Nerve. 2017 Jun;55(6):835-840. doi: 10.1002/mus.25413. Epub 2017 Feb 3.

Abstract

Introduction: Pompe disease is characterized by absence or deficiency of acid α-glucosidase, and several causative mutations are known. In this study we report clinical and laboratory data in Iranian patients with late-onset Pompe disease (LOPD), focusing on population-specific mutations.

Methods: Clinical and laboratory data of 14 patients from 10 families with the diagnosis of LOPD were recorded. All had reduced enzyme activity on dried blood spot (DBS) analysis. Genetic investigation was performed to identify the underlying mutations.

Results: The age of onset ranged from <2 to 38 years. The clinical presentations were heterogeneous. Two siblings presented with foot drop. The most common mutation was c.(-32-13T>G). There were 4 novel mutations: c.(2040 + 2dup); c.(1650delG); c.(1837T>G); and c.(2596delG).

Conclusion: This is a comprehensive report of LOPD in Iranian patients. Distinct phenotypic and genotypic features in this population are highlighted. Muscle Nerve 55: 835-840, 2017.

Keywords: GAA gene mutation; Pompe disease; acid α-glucosidase; glycogen-storage disease type II; late-onset; myopathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Consanguinity
  • Electromyography
  • Evoked Potentials, Motor / genetics
  • Family Health
  • Female
  • Genetic Predisposition to Disease / genetics*
  • Genotype
  • Glycogen Storage Disease Type II* / diagnosis
  • Glycogen Storage Disease Type II* / genetics
  • Glycogen Storage Disease Type II* / therapy
  • Humans
  • Iran / epidemiology
  • Male
  • Middle Aged
  • Muscle, Skeletal / physiopathology
  • Mutation / genetics*
  • Respiration Disorders / etiology
  • Young Adult
  • alpha-Glucosidases / genetics*

Substances

  • alpha-Glucosidases